These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 19916992)
1. Influence of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir and its active metabolite. Damle BD; Uderman H; Biswas P; Crownover P; Lin C; Glue P Br J Clin Pharmacol; 2009 Nov; 68(5):682-9. PubMed ID: 19916992 [TBL] [Abstract][Full Text] [Related]
2. Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patients. Hirt D; Mentré F; Tran A; Rey E; Auleley S; Salmon D; Duval X; Tréluyer JM; Br J Clin Pharmacol; 2008 Apr; 65(4):548-57. PubMed ID: 17922881 [TBL] [Abstract][Full Text] [Related]
4. Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus-infected patients with chronic liver disease. Khaliq Y; Gallicano K; Seguin I; Fyke K; Carignan G; Bulman D; Badley A; Cameron DW Br J Clin Pharmacol; 2000 Aug; 50(2):108-15. PubMed ID: 10930962 [TBL] [Abstract][Full Text] [Related]
5. Conversion of the HIV protease inhibitor nelfinavir to a bioactive metabolite by human liver CYP2C19. Hirani VN; Raucy JL; Lasker JM Drug Metab Dispos; 2004 Dec; 32(12):1462-7. PubMed ID: 15448116 [TBL] [Abstract][Full Text] [Related]
6. The effect of β-carotene supplementation on the pharmacokinetics of nelfinavir and its active metabolite M8 in HIV-1-infected patients. Sheehan NL; van Heeswijk RP; Foster BC; Akhtar H; Singhal N; Seguin I; DelBalso L; Bourbeau M; Chauhan BM; Boulassel MR; Burger DM; Lalonde RG; Cameron DW Molecules; 2012 Jan; 17(1):688-702. PubMed ID: 22241465 [TBL] [Abstract][Full Text] [Related]
7. The effect of the CYP2C19*2 heterozygote genotype on the pharmacokinetics of nelfinavir. Burger DM; Schwietert HR; Colbers EP; Becker M Br J Clin Pharmacol; 2006 Aug; 62(2):250-2. PubMed ID: 16842404 [No Abstract] [Full Text] [Related]
8. The pharmacokinetics of nelfinavir and M8 during pregnancy and post partum. van Heeswijk RP; Khaliq Y; Gallicano KD; Bourbeau M; Seguin I; Phillips EJ; Cameron DW Clin Pharmacol Ther; 2004 Dec; 76(6):588-97. PubMed ID: 15592330 [TBL] [Abstract][Full Text] [Related]
9. Impact of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir in patients with pancreatic cancer. Kattel K; Evande R; Tan C; Mondal G; Grem JL; Mahato RI Br J Clin Pharmacol; 2015 Aug; 80(2):267-75. PubMed ID: 25752914 [TBL] [Abstract][Full Text] [Related]
10. Pregnancy-related effects on nelfinavir-M8 pharmacokinetics: a population study with 133 women. Hirt D; Treluyer JM; Jullien V; Firtion G; Chappuy H; Rey E; Pons G; Mandelbrot L; Urien S Antimicrob Agents Chemother; 2006 Jun; 50(6):2079-86. PubMed ID: 16723569 [TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetic analysis for nelfinavir and its metabolite M8 in virologically controlled HIV-infected patients on HAART. Panhard X; Goujard C; Legrand M; Taburet AM; Diquet B; Mentré F; Br J Clin Pharmacol; 2005 Oct; 60(4):390-403. PubMed ID: 16187971 [TBL] [Abstract][Full Text] [Related]
13. Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P-glycoprotein expression. Ford J; Cornforth D; Hoggard PG; Cuthbertson Z; Meaden ER; Williams I; Johnson M; Daniels E; Hsyu P; Back DJ; Khoo SH Antivir Ther; 2004 Feb; 9(1):77-84. PubMed ID: 15040539 [TBL] [Abstract][Full Text] [Related]
14. Effects of standard and supratherapeutic doses of nelfinavir on cardiac repolarization: a thorough QT study. Damle B; Fosser C; Ito K; Tran A; Clax P; Uderman H; Glue P J Clin Pharmacol; 2009 Mar; 49(3):291-300. PubMed ID: 19246729 [TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacokinetics of nelfinavir and its metabolite M8 in human immunodeficiency virus (HIV)-positive and HIV-hepatitis C virus-coinfected subjects. Regazzi M; Maserati R; Villani P; Cusato M; Zucchi P; Briganti E; Roda R; Sacchelli L; Gatti F; Delle Foglie P; Nardini G; Fabris P; Mori F; Castelli P; Testa L Antimicrob Agents Chemother; 2005 Feb; 49(2):643-9. PubMed ID: 15673746 [TBL] [Abstract][Full Text] [Related]
16. Analysis of variation in plasma concentrations of nelfinavir and its active metabolite M8 in HIV-positive patients. Baede-van Dijk PA; Hugen PW; Verweij-van Wissen CP; Koopmans PP; Burger DM; Hekster YA AIDS; 2001 May; 15(8):991-8. PubMed ID: 11399981 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, food intake requirements and tolerability of once-daily combinations of nelfinavir and low-dose ritonavir in healthy volunteers. Aarnoutse RE; Droste JA; van Oosterhout JJ; Koopmans PP; Popescu M; Reiss P; Hekster YA; Burger DM Br J Clin Pharmacol; 2003 Feb; 55(2):115-25. PubMed ID: 12580982 [TBL] [Abstract][Full Text] [Related]
18. Effect of efavirenz treatment on the pharmacokinetics of nelfinavir boosted by ritonavir in healthy volunteers. la Porte CJ; de Graaff-Teulen MJ; Colbers EP; Voncken DS; Ibanez SM; Koopmans PP; Hekster YA; Burger DM Br J Clin Pharmacol; 2004 Dec; 58(6):632-40. PubMed ID: 15563361 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of Increased Nelfinavir Plasma Concentrations in Women During Pregnancy and Postpartum. Eke AC; McCormack SA; Best BM; Stek AM; Wang J; Kreitchmann R; Shapiro D; Smith E; Mofenson LM; Capparelli EV; Mirochnick M; J Clin Pharmacol; 2019 Mar; 59(3):386-393. PubMed ID: 30358179 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1. Litalien C; Faye A; Compagnucci A; Giaquinto C; Harper L; Gibb DM; Jacqz-Aigrain E; Pediatr Infect Dis J; 2003 Jan; 22(1):48-55. PubMed ID: 12544409 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]